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Resistant hypertension (RH) is a powerful risk factor for cardiovascular morbidity and mortality. Among the characteristics
of patients with RH, obesity, obstructive sleep apnea, and aldosterone excess are covering a great area of the mosaic of RH
phenotype. Increased sympathetic nervous system (SNS) activity is present in all these underlying conditions, supporting its
crucial role in the pathophysiology of antihypertensive treatment resistance. Current clinical and experimental knowledge points
towards an impact of several factors on SNS activation, namely, insulin resistance, adipokines, endothelial dysfunction, cyclic
intermittent hypoxaemia, aldosterone eﬀects on central nervous system, chemoreceptors, and baroreceptors dysregulation. The
further investigation and understanding of the mechanisms leading to SNS activation could reveal novel therapeutic targets and
expand our treatment options in the challenging management of RH.
1.Introduction
A number of physiological mechanisms are involved in
the maintenance of normal blood pressure (BP), and their
derangement may play a key role in the development of
hypertension (HTN). Amongst other factors, unfavorable
genetic substrate, activated sympathetic nervous system
(SNS) and renin-angiotensin system, excess sodium intake
and disturbances between vasoconstrictors and vasodilators
have been implicated in the pathophysiology of HTN [1].
Although the role of the above factors in the pathogenesis
of essential HTN is well established, their involvement in
mechanisms responsible for treatment resistance is not so
thoroughly investigated.
According to World Health Report 2002, suboptimal
BP control is the most common attributable risk for death
worldwide, being responsible for 62% of cerebrovascular
disease and 49% of ischemic heart disease [2, 3]. Since
resistance to treatment is one of the reasons for uncontrolled
BP, it is obvious that resistant hypertension (RH) entails
a major clinical and social impact. Consequently, under-
standing of the mechanisms involved in the pathophysiology
oftreatmentresistanceiscrucialforthedevelopmentofmore
eﬀective therapeutic strategies. In the present paper, we will
focus on the role of SNS in the pathophysiology of RH.
2. SNS and Patterns of Hypertension
The development of novel and sophisticated techniques for
the direct and indirect assessment of adrenergic activity has
changed our conception about the role of SNS in the regu-
lation of BP, from a short-term regulator to a cornerstone of
the pathogenesis and pathophysiology of HTN. Nowadays,
the established theory is that SNS hyperactivity contributes
to initiation, maintenance and progression of HTN. Sev-
eral studies have correlated adrenergic hyperactivity with
multiple patterns of HTN. More speciﬁcally, increased
SNS activity has been documented in systole-diastolic and
isolated systolic HTN [4, 5], in white coat and masked HTN
[4, 6], in dipping, extreme dipping, nondipping and reverse
dipping conditions [4, 7] and in pregnancy-induced HTN
[4, 8]. Furthermore, SNS activity increases progressively and
in parallel with HTN stages. This implies that the more2 International Journal of Hypertension
advanced the stage of HTN the greater is the adrenergic
activity[4,9,10].Whetherthiscorrelationcouldbeextended
toRHremainsuncleargiventhattheSNSactivityinresistant
hypertensives has been assessed in subgroups of populations
of intervention studies without comparison with healthy
controls.
3. The “Phenotype” of Resistant Hypertension
AccordingtotheAHAscientiﬁcstatementforRH[11],based
on the demographic data and the results of Framingham
and ALLHAT studies, the strongest predictors of lack of BP
control were older age, high baseline BP, obesity, excessive
dietary salt ingestion and chronic kidney disease. Aging and
its interface with SNS activation is well documented. A num-
ber of studies have shown that whole body sympathetic
neural activity increases with aging [12–16] and indices of
sympathetic activity, especially muscle sympathetic nerve
activity (MSNA), become more linked to BP with older age
[12, 17].
Beyond ageing, obesity, aldosterone excess and obstruc-
tivesleepapnea(OSA)arecoveringagreatareaofthemosaic
of the characteristics of resistant hypertensives. In cohorts
of patients with RH, the mean body mass index (BMI) was
over 32kg/m2 and the prevalence of hyperaldosteronism was
approximately 20% while the resistant hypertensives had
averyhighprevalenceofknownandsuspectedOSA[18–20].
Moreover, among subjects with RH, hyperaldosteronism was
more likely to be present in patients with conﬁrmed OSA
than in those at low risk for OSA. The existing data support
that OSA, aldosterone excess and obesity are not only
common comorbidities in resistant hypertensives but that
they also interact in this setting. Although the mechanisms
that link these conditions in RH are not fully elucidated, SNS
activation may be a major contributing factor (Figure 1).
4. The Interplay of SNS Activation and
Resistant Hypertension
4.1. Obesity. Obesity is associated with more severe HTN,
a need for an increased number of medications and
a decreased likelihood of achieving BP control [11]. The
Framingham study showed that subjects with BMI ≥
30kg/m2 had1.5-foldincreasedriskforuncontrolledsystolic
BPversussubjectswithBMI<25kg/m2 [21].Inaddition,the
HYDRA study, a cross-sectional study of 45,125 unselected
consecutive primary care attendees conducted in Germany,
showed that BP levels were consistently higher in obese
patients and the odds ratios for BP control in diagnosed
and treated patients were 0.8, 0.6, 0.5 and 0.7 for overweight
and grade 1, 2, and 3 obese patients, respectively, compared
to those with normal weight [22]. Among the mecha-
nisms involved in obesity-induced hypertension, apart from
impaired sodium excretion, ﬂuid retention and activation of
the renin-angiotensin-aldosterone system, the “neuroadren-
ergic hypothesis” should be taken into consideration.
Before the application of more speciﬁc methodology
for the estimation of SNS activity, including the direct
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Figure 1: A proposed pathophysiologic pathway for the activation
of SNS and the development of RH. Obesity, OSA and aldosterone
excess are covering a great area of the mosaic of the phenotype
of RH and are correlated with increased SNS activity, via multiple
mechanisms. ↑ALDO: Aldosterone excess, OSA: Obstructive sleep
apnea, ↑RAAS: Renin-Angiotensin-Aldosterone System activation,
RH: Resistant hypertension, ↑SNS: Sympathetic nervous system
hyperactivity.
recordingsofsympatheticnerveﬁringsandthemeasurement
of norepinephrine spillover to plasma, there was controversy
concerning the state of SNS function in human obesity.
These novel techniques applied to obese subjects with
normal BP documented that the sympathetic outﬂow was
increased to the kidneys and skeletal muscle vasculature,
while it was normal to skin and the hepatomesenteric cir-
culation and reduced to the heart [23–26]. This regional
heterogeneity of SNS activation in obese normotensives is
mitigated in hypertensives where a more homogenous
activation of the SNS has been reported with absence of the
suppression of cardiac sympathetic outﬂow [25–27]. Finally,
the distribution of the adipose tissue seems to be crucial for
the activation of the SNS since the central pattern of obesity
withexcessofvisceralfatisaccompaniedbyincreasedMSNA
incontrasttomenwithperipheralobesitywhereMSNAisno
higher than in lean men [23, 28, 29].
Several mechanisms have been proposed to explain the
SNS activation in obese subjects; increased leptin concen-
tration,hyperinsulinemia,OSA,decreasedarterialbaroreﬂex
sensitivity, elevated plasma angiotensin, obesity-related kid-
ney disease and lack of exercise [23]. Findings of increased
MSNA after infusion of insulin in humans could suggest
a triggering role of insulin for the SNS [30]. On the other
hand, the same procedure in lean hypertensives does not
seem to activate the renal sympathetic nerves [31]. Given
that obesity is accompanied by increased renal sympathetic
activity, mechanisms other than hyperinsulinemia should be
considered, taking into account that insulin resistance might
be an epiphenomenon of SNS activation. Furthermore,
signals arising in adipose tissue that activate the brain haveInternational Journal of Hypertension 3
been ascribed to adipokines such as leptin. The eﬀects of
leptin on the SNS are thought to be mainly driven by
binding to leptin receptors in the hypothalamus [32]. Cross-
sectional studies have shown positive correlations between
leptin concentration and various indices of sympathetic acti-
vation [33–35]. However, the results of intervention studies
examining the eﬀects of leptin infusion on sympathetic
activitystatusarecontroversial[36–38].Additionallytothese
centrally driven eﬀects, nonneural eﬀects of leptin on the
cardiovascular system mediated through receptors in the
heart and endothelium are supported by the independent
association between circulating leptin and heart rate in
denervated hearts of transplanted patients [39]. Finally,
evidence supports a bidirectional relationship between the
renin-angiotensin system and SNS. The stimulation of
renin release from juxtaglomerular granular cells through
renal sympathetic nerves is well documented [40], while
angiotensin facilitates adrenergic function at the level of
central and peripheral nervous system [41, 42]. Grassi et al.
reported substantial sympathetic inhibition by angiotensin
receptor blockade in obesity-related hypertension [43]
which is not produced in lean men with or without HTN
[44, 45].
4.2. Obstructive Sleep Apnea. OSA and HTN are strongly
associated, since OSA is an independent predictor for
the presence and future development of HTN [46, 47].
The Wisconsin Sleep Cohort study, a prospective study
of the association between sleep-disordered breathing and
HTN in 709 subjects, reported a dose-response association
between sleep-disordered breathing at baseline and the
presence of HTN four-years later that was independent
of known confounding factors [48]. This association is
particularly strong in patients with RH. In a series of 41
resistant hypertensives, the prevalence of OSA, diagnosed
by overnight polysomnographic study, was 83% and both
the prevalence and the severity were signiﬁcantly higher
i nm e nt h a ni nw o m e n[ 19]. In case-control studies, OSA
was strongly and independently associated with RH and the
apnoeic patients had 4- to 4.8-fold increased risk of having
RH [49, 50].
Increased levels of norepinephrine, endothelin and al-
dosterone, vascular stiﬀening, activation of the renin-
angiotensin system, endothelial dysfunction, oxidative stress
and SNS hyperactivity have been suggested as explanations
for sleep apnea-induced HTN [50–52]. According to the
classic systematic review of Coy et al. all studies using MSNA
revealed a relationship between sleep apnea and an increase
in MSNA. Of the 21 catecholamine papers reviewed, only
four failed to report a relationship between OSA and levels
of either norepinephrine or epinephrine [53]. Assessment
of MSNA has shown a sustained increase in sympathetic
output which is increased even during the daytime and in
the presence of normoxic wakefulness [54]. Furthermore,
sympathetic traﬃc to peripheral blood vessels was higher
in OSA subjects compared to controls with no diﬀerence
b e t w e e nn o r m o t e n s i v e sa n dh y p e r t e n s i v e s[ 55]. The inde-
pendent activation of the SNS in apnoeics, regardless of
comorbidities, is also documented in obesity. Sympathetic
activity in lean men with OSA was elevated to a similar
degree as in obese men without OSA, but less than in those
with both OSA and obesity, in whom the two conditions
exerted an additive eﬀect [56]. Patients with OSA also have
faster heart rates during resting wakefulness, suggesting an
increasedcardiacsympatheticoutﬂow[57].Furtherevidence
of SNS activation by OSA is provided by studies reporting
a reduction in SNS activity after continuous positive airway
pressure (CPAP) therapy. In the study of Narkiewicz et al.
the decrease of MSNA was evident after both 6 months
and 1 year of CPAP therapy [58]. In another study, the
decrease in sympathetic activity, estimated by peroneal
microneurography at least 1 month after CPAP treatment,
was limited to the patients with greater compliance with this
device (>4.5 hours/night) [59]. On the other hand, when
adrenergic activity was estimated by norepinephrine kinetics
and the CPAP treatment was delivered for 14 days, the
reduction in plasma levels of norepinephrine was attributed
to increased norepinephrine clearance [60].
There seems to be a causalrelationship between OSA and
SNSactivation,despitethelackofestablishedmechanismsby
which nocturnal upper airway obstructions leads to daytime
sympathetic activation. Both the arousals from sleep and
transient hypoxemia, the two major characteristics of OSA
syndrome, have been proposed as a linkage between OSA
and SNS hyperactivity. However, it is not clear if arousals
can inﬂuence daytime adrenergic status independently from
respiratory disturbances during sleep [61]. When daytime
plasma norepinephrine levels were used as an index of
daytime sympathetic tone, there was a correlation with
movement, but not cortical arousals [62]. On the con-
trary, the data supporting cyclic intermittent hypoxaemia
as the stimulus to SNS activation are more robust. The
eﬀerent sympathetic outﬂow is inﬂuenced by peripheral
reﬂex activity, via chemoreceptors and baroreceptors, as
well as by central sympathetic activity. Peripheral arterial
chemoreceptors have a signiﬁcant physiological activity
in normoxia, the so-called “resting drive”. Interestingly,
administration of 100% oxygen, leading to chemoreﬂex
deactivation, is accompanied by a decrease in both MSNA
and BP in patients with OSA but not in nonapnoeic
control subjects [63]. Thus, elevated MSNA in patients
with OSA might be explained in part by tonic activa-
tion of excitatory chemoreﬂex aﬀerents. Molecules such as
endothelin and angiotensin II with a stimulating eﬀect on
chemosensitivity have been implicated in the mechanisms by
which OSA results in increased chemoresponsivness through
cyclic intermittent hypoxaemia [64]. Findings of increased
expression of the endothelin receptor A and of preproen-
dothelin, and also of upregulation of transcriptional and
post-transcriptional expression of angiotensin type 1 recep-
tors, in the carotid body after hypoxia, suggest that these
molecules may inﬂuence sympathetic activity by modulating
peripheral chemoreﬂex sensitivity after exposure to cyclic
intermittent hypoxaemia [64, 65]. Furthermore, evidence
support that these molecules can serve as neuromodula-
tors of sympathetic activity in the central nervous system
[64].4 International Journal of Hypertension
4.3. Excess of Aldosterone. A growing body of evidence
suggests that aldosterone contributes broadly to the devel-
opment and severity of HTN separately from the presence
of classically deﬁned primary aldosteronism. The ongoing
FraminghamOﬀspringstudyshowedthatserumaldosterone
levels in normotensive subjects predicted the development
of incident HTN and that the patients in the highest serum
aldosterone quartile, relative to the lowest had a 1.6-fold
risk of HTN during a four-year follow-up [66]. Moreover,
a positive correlation was documented between plasma
aldosterone and 24-hour ambulatory BP in cross sectional
studies [67, 68]. Among untreated patients, the prevalence
of primary aldosteronism increases with the stage of HTN
(according to the JNC VI), from 2% in patients with stage 1
HTNto8%inthosewithstage2HTNand13%inthosewith
stage 3 HTN [69]. The prevalence of primary aldosteronism
is even higher in patients with RH, approaching 17–22% in
multiple studies [70–72]. Furthermore, individuals with true
RH but without primary hyperaldosteronism have higher
aldosterone levels than control participants [73]. These
ﬁndings suggest that aldosterone excess commonly underlies
resistance to antihypertensive treatment.
The classic eﬀects of aldosterone are exerted on the renal
handling of sodium and potassium leading to expansion
of intravascular volume and hypokalemia. In addition,
aldosterone promotes RH by mediating maladaptive changes
in the renal, cardiovascular and central nervous systems
[74,75].SNSactivationseemstobeabasiccomponentofthe
adverse impact of aldosterone excess in the central nervous
system. In a cross-over study, sustained SNS stimulation was
identiﬁedduringchlorthalidoneadministrationtohyperten-
sives but not during spironolactone [76]. A recent double-
blind, randomized study by Wray et al. reported a signiﬁcant
reduction in SNS activity after six months of therapy with
an aldosterone receptor blocker, which was achieved without
a change in end organ a-adrenergic responsiveness, implicat-
ingacentralmechanismforthechangeinautonomicactivity
[77]. The above data extend earlier work in animal models
demonstrating the ability of aldosterone receptor blockade
to decrease SNS activity in hypertensive mouse models [78].
The mechanisms of aldosterone mediated central SNS
activation are becoming clearer. The mineralocorticoid
receptor is expressed in many cell types, including speciﬁc
neurons. Mineralocorticoid receptors in the paraventricular
nuclei are involved in the augmented neuronal activity in the
nuclei leading to increased sympathetic drive [79]. Multiple
studies in animal models are intensively investigating poten-
tial pathophysiological pathways. Indicatively, data arising
from rats with heart failure demonstrate that mineralo-
corticoid receptor blockade reduces nicotinaminase adenine
dinucleotide phosphate (NADPH) induced superoxide in
the paraventicular nuclei of the hypothalamus and reduces
descending sympathetic paraventricular nuclei output [80].
5. ClinicalApplications
Although the clinical investigation has increased our knowl-
edgeaboutthefunctionoftheSNSanditsinvolvementinthe
pathophysiology of several cardiovascular diseases including
HTN,thereisnocurrentrecommendationfortheestimation
of adrenergic activity in resistant hypertensives. Despite the
methodological achievements in the assessment of adrener-
gic function, reﬂected in microneurographic measurement
of MSNA and measurement of organ speciﬁc noradrenaline
spillover, no technique can be viewed as the “gold standard”
[81], and the above techniques are mainly used for investi-
gational purposes. Regarding the most clinically applicable
methods of hemodynamic parameters and noradrenaline
measurement in urine and plasma, their limitations should
be mentioned. Resting heart rate and heart rate responses
to stimuli are regulated not only by the SNS but also by the
parasympathetic nervous system and they are also depended
on cardiac adrenergic receptors [81]. Furthermore, supine
heart rate displays only a limited correlation with other
indices of sympathetic activity, as plasma norepinephrine
and sympathetic nerve traﬃc[ 82]. Concerning 24 hour
urinaryexcretionofcatecholamines,theinabilityofdynamic
assessment of the SNS activity, the weakness to determine
the systematic or renal origin of catecholamines and the
dependence on renal function should be underlined [83]. As
regards plasma noradrenaline levels, low reproducibility, low
sensitivityandbiologicalrestrictionstodiscriminatebetween
increased secretion or reduced clearance of elevated cir-
culating neurotransmitter constitute substantial limitations
[81, 84].
The therapeutic strategy in RH aims to block all pos-
sible mechanisms for BP elevation. Combination therapy
with appropriate diuretic selection and dosing remains the
cornerstone of treatment. According to the 2007 ESC/ESH
guidelines for the management of arterial hypertension,
patientswithRHwillneedadministrationofmorethanthree
drugs [85]. Studies suggest that adding spironolactone or
eplerenonetoexisting antihypertensive regimens forpatients
with RH provides signiﬁcant BP reduction [11, 85, 86]. Most
importantly, reductions in BP were similar in patients with
and without primary aldosteronism and were not predicted
by baseline plasma or 24 hour urinary aldosterone, plasma
renin activity or plasma aldosterone to renin ratio [87].
With the usual therapeutic options the SNS hyperactivity
is blocked to the peripheral level of adrenergic receptors
with the use of alpha and beta blockers and it should be
mentioned once more that rising data suggest a sympathoin-
hibitory eﬀect of angiotensin and mineralocorticoid receptor
blocking [43, 76, 77]. Centrally acting agents are eﬀective
antihypertensive agents but have a high incidence of adverse
eﬀects and lack outcome data [11]. Finally, promising
results arrive from recent studies of interventional methods
of sympathoinhibition including activation of the carotid
baroreceptors using electrical stimuli [88] and selective renal
sympathetic denervation [89].
6. Conclusions
Obesity, OSA, and aldosterone excess are common comor-
bidities in resistant hypertensives. Screening of these under-
lying conditions in patients with RH is of major clinicalInternational Journal of Hypertension 5
importance. SNS hyperactivity is a common characteristic
of all the above conditions supporting its crucial role in
the pathophysiology of antihypertensive treatment resis-
tance. The further investigation and understanding of the
mechanisms leading to SNS activation could reveal novel
therapeutic targets and expand our treatment options in the
challenging management of RH.
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